Emergence of Tigecycline Resistance in Multidrug Resistant (MDR) Organisms Isolated At Tertiary Care Hospital, Ahmedabad
Emergence of Tigecycline Resistance in Multidrug Resistant (MDR) Organisms Isolated
DOI:
https://doi.org/10.70284/njirm.v8i2.1226Keywords:
Tigecycline, MDR, E-test, MIC, Acinetobacter, MRSA, VRE, EnterobacteriaceaeAbstract
Objective & Background: Tigecycline is the first glycylcycline antibiotic to be approved by US Food and Drug Administration (FDA) and therapeutic agent for serious infections caused by multidrug resistant organism. This study is to evaluate the emergence of Tigecycline resistance in MDR organisms. Method: This study was conducted over a period of July 2016 to 15th Nov 2016. A total of 217 Multi Drug Resistant Organisms (MDRO) isolated from various clinical specimens except urine, as per standard protocols and antibiotic sensitivity. Out of which 36 Methicillin Resistant Staphylococcus ( MRSA) , 3 Vancomycin Resistant Enterococci (VRE) ,91 Multidrug resistant Acinetobacter spp and 87 MDR Enterobacteriaceae, are tested for Tigecycline (TIG) resistance by disc diffusion Method and Minimum inhibitory concentration (MIC) was determined by E-test gradient strip. Result: All the isolates for MRSA, VRE shows 0% resistant to Tigecycline but 6 (6.89%) of MDR Enterobactiaceae and 15 (16.48 %) of MDR Acinetobacter spp. were found to be resistant to Tigecycline. Conclusion: Tigecycline was found to be highly effective against gram positive bacteria and resistance is observed in Acinetobacter spp. and Enterobacteriaceae, especially in multidrug-resistant strains. So before starting the treatment, susceptibility to Tigecycline should be assessed, to prevent the development and the dissemination of resistance against this one of the last available promising and safe therapeutic options which is available to the clinicians for combating these bacteria. [Mamta K NJIRM 2017; 8(2):153-157]
References
2. G. Bauer, C. Berens, S.J. Projan, W. Hillen CAAomparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S RrnaJ AntimicrobChemother, 53 (2004), pp. 592–599 Cross Ref View Record in ScopusCiting articles (121)
3. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in north India. Indian J Med Res 2006; 124: 95-8.
4. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producingGram-negative bacteria in a tertiary care hospital. Indian J Med Res 2002; 115: 153-7.
5. a. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing, 26th ed. CLSI supplements, MO2-A12, M100S, 26th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2016.
6. b. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22 Wayne (PA): Clinical and Laboratory Standards Institute; 2016.
7. Dhawan B, Mohanty S, Das BK, Kapil A. Antimicrobial susceptibility patterns of Staphylococci in a tertiary care hospital. Natl Med J India 2004; 17 : 52-3.
8. Vancomycin resistant enterococci in a tertiary care hospital in Mumbai, Department of Microbiology, L.T.M. Medical College, Sion, Mumbai - 400 022, India
9. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. Imipenem-EDTA disk method for diffentiation of metallo-β- lactamase-producing clinical isolates of pseudomonas spp. and Acinetobacter spp. J Chin Microbiol 2002;40:3798-80 1
10. Wyeth Pharmaceuticals. Tygacil (Tigecycline) for injection [Package insert]. 2005. Wyeth Pharmaceuticals Inc., Philadelphia, PA.
11. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of Tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J ClinMicrobiol 2007; 45: 2173-9
12. Cunha BA, McDermott B, Nausheen S. 2007. Single daily high-dose Tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J. Chemother. 19:753–754.
13. Daly MW, Riddle DJ, Ledeboer NA, Dunne WM, Ritchie DJ. 2007. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27:1052– 1057.
14. Doan TL, Fung HB, Mehta D, Riska PF. 2006. Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther. 28:1079 –1106.
15. Bijayini Behera, Anupam Das* , Purva Mathur, ArtiKapil* , RavisekharGadepalli* &BenuDhawan* Department of Laboratory Medicine, Jai Prakash
Narayan Apex Trauma Centre & *Department of Microbiology All India Institute of Medical Sciences, C.K. Kim, Y. Lee, H. Lee, G.J. Woo, W. Song, M.N. Kim, et al.
16. Dipender Kaur Najotra et al., In vitro activity of tigecycline against MDR Acinetobacter
17. G.F. Araj, G.Y. Ibrahim Tigecycline in vitro activity against commonly encountered multidrug-resistant Gram-negative pathogens in a Middle Eastern country Diagn Microbiol Infect Dis, 62 (2008), pp. 411–415Article PDF (157 K)View Record in Scopus
18. R. Naesens, J.P. Ursi, J. Van Schaeren, A. Jeurissen ,In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospitalEur J ClinMicrobiol Infect Dis, 28 (2009), pp. 381–384
19. View Record in Scopus D.M. Livermore, M. Warner, S. Mushtaq, M. Doumith, J. Zhang, N. Woodford What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecyclineInt J Antimicrob Agents, 37 (2011), pp. 415–41 Article PDF (135 K)
20. Prevalence and diversity of carbapenemases among imipenem-nonsusceptible Acinetobacter isolates in Korea: emergence of a novel OXA-182 DiagnMicrobiol Infect Dis, 68 (2010), pp. 432–438M Article PDF (610 K)View Record in Scopus
21. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse E J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41 (Suppl 5) : S 333-40.
